Developing novel chemistries for removing environmental surface biofilms to reduce hospital acquired infections. This project will develop new detergents that more efficiently clean hospitals. This will increase hospital safety by decreasing infections, thus saving lives and healthcare costs.
New models as tools for defining mechanisms of microbe survival in the urogenital tract. Bacteria that infect the human urogenital tract can cause serious disease and these infections represent a large cost to the health-care system world-wide. This study will focus on how bacteria survive in the human urogenital tract and this will impact on strategies aimed at preventing and treating these infections.
A single vaccine for influenza and pneumonia. Influenza and bacterial pneumonia collaborate to kill millions of people each year. This project aims to develop a single vaccine that will provide long-lasting protection against both influenza and pneumonia.
The development and evaluation of a new therapy for the prevention and treatment of bacterial infections in hospitals. The technology used in this project will enable products to be developed from the Australian dairy industry which may safely provide protection and treatment for diarrhoea acquired in hospitals for which there are few effective options. The product will be cost effective and can be used as a public health tool to control outbreaks in those most susceptible to severe disease.
Host-pathogen interactions: the role of mimicry. The proposed research program, using a combination of structure and functional analysis will provide insight into the mechanism of nucleotide hydrolysis by the enzymes NTPDases. This study will not only improve our fundamental understanding of NTPDase action but could lead to the rational design of antimicrobials.
Functional characterisation of poly-histidine triad proteins. This project aims to understand the role and function of a novel family of surface proteins produced by Streptococci. These so-called polyhistidine triad proteins are known to contribute to capacity to cause disease in animals and humans, but we need to know how they work, as they may be excellent targets for novel drugs or vaccines.
Novel perspectives on the function of AB5 toxin B subunits in pathogenic bacterial. AB5 toxins are produced by bacteria that cause important diseases in humans and livestock. This project tests the hypothesis that the components of the toxins responsible for binding to host cells and tissues also directly contribute to cellular damage, thereby providing a better understanding of how AB5 toxin-producing bacteria cause disease.
Discovery Early Career Researcher Award - Grant ID: DE120103084
Funder
Australian Research Council
Funding Amount
$375,000.00
Summary
Targeting bacterial superbugs: novel approaches for optimisation of antibiotic combinations and resistance prevention. This project will elucidate the mechanistic basis to optimally combine available beta-lactam antibiotics to prevent resistance of gram-negative 'superbugs'. The interdisciplinary project will substantially contribute to solving the global crisis due to multidrug-resistant bacteria and inform the design of effective new antibiotics.
Discovery Early Career Researcher Award - Grant ID: DE120101340
Funder
Australian Research Council
Funding Amount
$375,000.00
Summary
Subversion of innate immune responses by pathogenic Escherichia coli. This project will determine how bacteria that cause diarrhoeal diseases prevent the immune system from signalling efficiently. It will provide important information not only about how the bacteria establish disease, but also provide insight into the host response in the early stages of infection.
Targeting an impending global disaster: the mismatch between increasingly drug-resistant superbugs and development of new antibiotics. This project will develop much-needed novel antibiotics for treating infections caused by bacteria that are resistant to all current antibiotics. It will make a significant contribution to the global medical challenge of a shortage of new antibiotics.